Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HF158K1 |
| Synonyms | |
| Therapy Description |
HF158K1 is an immunoliposome containing doxorubicin and TL01, an ERBB2 (HER2)-targeted trastuzumab Fab fragment conjugated lipid, which delivers doxirubicin to ERBB2 (HER2)-expressing tumor cells and potentially inhibits DNA replication (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HF158K1 | HF-158K1|HF 158K1 | HF158K1 is an immunoliposome containing doxorubicin and TL01, an ERBB2 (HER2)-targeted trastuzumab Fab fragment conjugated lipid, which delivers doxirubicin to ERBB2 (HER2)-expressing tumor cells and potentially inhibits DNA replication (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05861895 | Phase I | HF158K1 | A Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of HF158K1 in Participants With HER-2 Positive or HER-2 Low Expression Advanced Solid Tumors | Recruiting | USA | 0 |